"Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7)" by Katherine R. Tuttle

Selected Works of Katherine R. Tuttle, MD, FASN, FACP, FNKF

Article

Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7)

Diabetes, Obesity and Metabolism (2019)

Katherine R. Tuttle, University of Washington
Mark C. Lakshmanan, Eli Lilly and Company
Brian Rayner, University of Cape Town
Alan G. Zimmermann, Eli Lilly and Company
D. Bradley Woodward, Eli Lilly and Company
Fady T. Botros, Eli Lilly and Company

Link

Disciplines

Medicine and Health Sciences,
Endocrinology, Diabetes, and Metabolism,
Internal Medicine and
Endocrinology

Publication Date

February 14, 2019

DOI

10.1111/dom.13668

Citation Information

Katherine R. Tuttle, Mark C. Lakshmanan, Brian Rayner, Alan G. Zimmermann, et al.. "Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7)" Diabetes, Obesity and Metabolism (2019)
Available at: http://works.bepress.com/katherine-tuttle/167/